SI2044111T1 - Ciljanje komplementa faktorja H za zdravljenje bolezni - Google Patents

Ciljanje komplementa faktorja H za zdravljenje bolezni

Info

Publication number
SI2044111T1
SI2044111T1 SI200731549T SI200731549T SI2044111T1 SI 2044111 T1 SI2044111 T1 SI 2044111T1 SI 200731549 T SI200731549 T SI 200731549T SI 200731549 T SI200731549 T SI 200731549T SI 2044111 T1 SI2044111 T1 SI 2044111T1
Authority
SI
Slovenia
Prior art keywords
diseases
treatment
complement factor
targeting complement
targeting
Prior art date
Application number
SI200731549T
Other languages
English (en)
Inventor
Gary Gilkeson
Stephen Tomlinson
V. Michael Holers
Baerbel Rohrer
Original Assignee
Musc Foundation For Research Development
The Regents Of The University Of Colorado, A Body Corporate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Musc Foundation For Research Development, The Regents Of The University Of Colorado, A Body Corporate filed Critical Musc Foundation For Research Development
Publication of SI2044111T1 publication Critical patent/SI2044111T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SI200731549T 2006-06-21 2007-06-21 Ciljanje komplementa faktorja H za zdravljenje bolezni SI2044111T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81574806P 2006-06-21 2006-06-21
PCT/US2007/014602 WO2007149567A2 (en) 2006-06-21 2007-06-21 Targeting complement factor h for treatment of diseases
EP07845250.5A EP2044111B1 (en) 2006-06-21 2007-06-21 Targeting complement factor h for treatment of diseases

Publications (1)

Publication Number Publication Date
SI2044111T1 true SI2044111T1 (sl) 2015-02-27

Family

ID=38695591

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731549T SI2044111T1 (sl) 2006-06-21 2007-06-21 Ciljanje komplementa faktorja H za zdravljenje bolezni

Country Status (14)

Country Link
US (3) US7759304B2 (sl)
EP (2) EP2044111B1 (sl)
JP (1) JP5250548B2 (sl)
CN (1) CN101563363B (sl)
AU (1) AU2007261315B2 (sl)
BR (1) BRPI0712987A2 (sl)
CA (1) CA2656063C (sl)
DK (1) DK2044111T3 (sl)
ES (1) ES2523640T3 (sl)
HK (2) HK1129689A1 (sl)
PL (1) PL2044111T3 (sl)
PT (1) PT2044111E (sl)
SI (1) SI2044111T1 (sl)
WO (1) WO2007149567A2 (sl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
AU2003298650B2 (en) * 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
CN103505728A (zh) * 2005-05-26 2014-01-15 科罗拉多大学评议会法人机构 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
ES2523640T3 (es) 2006-06-21 2014-11-28 Musc Foundation For Research Development Direccionamiento del factor H del complemento para el tratamiento de enfermedades
EP2083841B1 (en) * 2006-10-20 2013-11-20 Celldex Therapeutics, Inc. SOLUBLE COMPLEMENT RECEPTOR TYPE I (sCR1) PROTEIN FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER DISEASES OF THE EYE
EP2118142A2 (en) 2007-03-14 2009-11-18 Taligen Therapeutics, Inc. Humaneered anti-factor b antibody
CA2687395C (en) * 2007-05-03 2017-07-11 Medizinische Universitat Innsbruck Complement factor h-derived short consensus repeat-antibody constructs
WO2009151634A1 (en) * 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
GB0904427D0 (en) * 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
ME01699B (me) * 2009-07-02 2014-09-20 Musc Found For Res Dev Metode za stimulaciju regeneracije jetre
MX2012005151A (es) 2009-11-05 2012-08-23 Federico Ii University Of Naples Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
GB0922659D0 (en) * 2009-12-24 2010-02-10 Univ Edinburgh Factor H
JP6148013B2 (ja) 2010-03-05 2017-06-14 リグショスピタレト 補体活性化のキメラ抑制分子
MX2012013233A (es) * 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
KR20130036276A (ko) * 2010-06-22 2013-04-11 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 보체 결합 3의 C3d 조각에 대한 항체들
US9988611B2 (en) 2011-12-01 2018-06-05 Ap Biosciences, Inc. Protein inhibitors to complement and VEGF pathways and methods of use thereof
FR2988298A1 (fr) * 2012-03-23 2013-09-27 Lfb Biotechnologies Facteur h pour son utilisation comme molecule antioxydante
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
AU2014236782B2 (en) * 2013-03-14 2019-01-03 Baxalta GmbH Factor H for treatment of rheumatoid arthritis
PT2968457T (pt) * 2013-03-14 2018-11-07 Baxalta Inc Fator h para transplante
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
CN104293901A (zh) * 2013-07-19 2015-01-21 金弗康生物科技(上海)有限公司 一种用于系统性红斑狼疮的早期诊断的检测试剂盒
EA034870B1 (ru) 2013-08-07 2020-03-31 Алексион Фармасьютикалз, Инк. Белковые биомаркеры атипичного гемолитического уремического синдрома
WO2015023972A1 (en) 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
US20150093331A1 (en) * 2013-10-01 2015-04-02 OncoLock Co., Ltd. Biomarkers for breast cancer
FR3015484A1 (fr) * 2013-12-20 2015-06-26 Lab Francais Du Fractionnement Proteines recombinantes possedant une activite de facteur h
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
MY191207A (en) * 2015-07-29 2022-06-08 Nat Univ Singapore A method of protecting a magnetic layer of a magnetic recording medium
US10988519B2 (en) * 2015-09-24 2021-04-27 The Trustees Of The University Of Pennsylvania Composition and method for treating complement-mediated disease
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
FR3046355A1 (fr) * 2015-12-30 2017-07-07 Lab Francais Du Fractionnement Fragments du facteur h pour son utilisation comme agent anti-angiogenique
CN106928371B (zh) * 2015-12-31 2021-06-08 江苏匡亚生物医药科技有限公司 具有补体调节活性的重组补体因子h-免疫球蛋白融合蛋白及其制备方法与应用
GB201709222D0 (en) * 2017-06-09 2017-07-26 Univ Manchester C3b Inactivating Polypeptide
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
AU2019266548A1 (en) * 2018-05-10 2021-01-07 Complement Therapeutics Limited Methods for assessing macular degeneration
WO2020041638A1 (en) * 2018-08-22 2020-02-27 Alexion Pharmaceuticals, Inc. Complement factor h and fc binding domain fusion proteins
US20220009979A1 (en) * 2018-08-22 2022-01-13 Alexion Pharmaceuticals, Inc. Fusion proteins and methods of treating complement dysregulation using the same
GB201821089D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Codon-optimised complement factor I
CN110330561B (zh) * 2019-05-27 2020-10-27 北京康普美特创新医药科技有限责任公司 人源靶向补体抑制物蛋白双突变体mCR2-mDAF及应用
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
EP4348263A1 (en) 2021-05-28 2024-04-10 Alexion Pharmaceuticals, Inc. Methods for detecting cm-tma biomarkers

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981481A (en) 1974-12-06 1999-11-09 The Johns Hopkins University Human C3b/C4b receptor (CR1)
US5212071A (en) 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5733254A (en) 1987-10-15 1998-03-31 Cypress Bioscience, Inc. Method for treating patients suffering from immune thrombocytopenic purpura
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
DE3830271A1 (de) 1988-09-06 1990-03-15 Goetze Otto Mittel mit immunsuppressiver wirkung
CA2345497A1 (en) 1988-10-28 1990-04-28 Genentech, Inc. Growth hormone variants and method for forming growth hormone variants
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0394538B1 (en) 1989-04-28 1996-10-16 Rhein Biotech Gesellschaft Für Neue Biotechnologische Prozesse Und Produkte Mbh A yeast cell of the genus schwanniomyces
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2648133B1 (fr) 1989-06-08 1992-02-21 Sanofi Sa Lauramides n-substitues, leur preparation et compositions les contenant
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5331090A (en) 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
US5310729A (en) 1990-04-20 1994-05-10 California Institute Of Biological Research Interferon-related polypeptides as CR2 ligands and their use for modulating immune cell functions
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
EP1413587A2 (en) 1991-05-03 2004-04-28 Washington University Modified complement system regulator
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
DK0788513T3 (da) 1994-10-25 2001-04-02 Glaxo Group Ltd Anvendelse af bindingsmidler for CD23 i behandlingen af atoimmune sygdomme
US5922320A (en) 1996-06-14 1999-07-13 Georgetown University Recombinant proCVF
WO1997047321A1 (en) 1996-06-14 1997-12-18 The Johns Hopkins University School Of Medicine Use of chimeric vaccinia virus complement control proteins to inhibit complement
JP2001514484A (ja) 1996-08-21 2001-09-11 スージェン・インコーポレーテッド タンパク質チロシンキナーゼの結晶構造
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
GB9624731D0 (en) 1996-11-28 1997-01-15 Univ Leicester Complement inhibitor
WO1999002567A2 (en) 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
WO1999037149A1 (en) * 1998-01-27 1999-07-29 Brigham & Women's Hospital Methods of treating cytotoxic damage
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
EP3056516A1 (en) 1998-02-20 2016-08-17 Genentech, Inc. Inhibitors of complement activation
WO1999044625A1 (en) 1998-03-03 1999-09-10 John Hopkins University Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
JP5138844B2 (ja) * 1998-06-12 2013-02-06 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド 抗原およびＥＢＶＧｐ３５０／２２０の受容体の同時刺激によるＢ細胞活性化および免疫グロブリン分泌の増強
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
EP1001021B1 (en) * 1998-09-25 2003-08-27 Wolfgang Prodinger Monoclonal antibody to human CD21, and its uses
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
CA2702148C (en) 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
DK1176981T3 (da) 1999-05-07 2006-04-10 Genentech Inc Behandling af autoimmune sygdomme med antagonister som binder til B celleoverflademarkörer
US7576182B1 (en) 1999-08-31 2009-08-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
GB0008582D0 (en) 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
WO2001084149A2 (en) 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US7439330B2 (en) 2000-05-08 2008-10-21 President And Fellows Of Harvard College Anti-glycated CD59 antibodies and uses thereof
MXPA03002262A (es) 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
ATE359807T1 (de) 2001-02-21 2007-05-15 Surromed Inc Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
JP2004529945A (ja) 2001-05-17 2004-09-30 ラ ホヤ ファーマシューティカル カンパニー Ｃｄ２１を阻害する薬剤を使用して抗体媒介性病理を処置する方法
US20030181531A1 (en) 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
WO2003018774A2 (en) 2001-08-29 2003-03-06 University Of Virginia Patent Foundation Therapeutic uses of complement receptor 2
WO2003047525A2 (en) 2001-12-03 2003-06-12 The Regents Of The University Of California Expression of glial-derived neurotrophic factor for treatment of diseases of the eye
EP1336618A1 (en) 2002-02-15 2003-08-20 HANS-KNÖLL-INSTITUT FÜR NATURSTOFF-FORSCHUNG e.V. Porcine complement regulator factor H and its use
US20030180292A1 (en) 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
AU2003218168A1 (en) 2002-03-15 2003-09-29 University Of Southern California Ophthalmic solutions for delivery of expression vectors
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
AU2003298650B2 (en) * 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
BRPI0408889A (pt) 2003-03-28 2006-04-11 Applied Research Systems uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
WO2004103288A2 (en) 2003-05-13 2004-12-02 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of preventing recurrent miscarriages
JP4029772B2 (ja) 2003-05-16 2008-01-09 株式会社日立製作所 磁気ヘッドおよびそれを用いた磁気記録再生装置
EP1488798A1 (en) 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure
AU2004263538B2 (en) 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US20050112130A1 (en) 2003-11-05 2005-05-26 Bhat Neelima M. Enhanced B cell cytotoxicity of CDIM binding antibody
US8454963B2 (en) * 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
CN1925871A (zh) 2004-01-27 2007-03-07 南加州大学 聚合物结合的抗体癌症治疗剂
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
CA2561531C (en) 2004-02-10 2017-05-02 The Regents Of The University Of Colorado Inhibition of factor b, the alternative complement pathway and methods related thereto
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
MX2007002557A (es) 2004-09-03 2007-10-10 Creabilis Therapeutics Spa Uso de polipeptidos obtenidos a traves de mutaciones sistematicas de aminoacidos unicos de bloque-a humano y no humano de hmgb1 para prevenir y/o antagonizar las patologias inducidas por hmgb1.
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
KR101290621B1 (ko) 2004-11-18 2013-07-29 더 락커펠러 유니버시티 안질환 치료용 방법 및 조성물
AU2006211625A1 (en) 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
NZ595305A (en) * 2005-02-14 2013-06-28 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
CN103505728A (zh) 2005-05-26 2014-01-15 科罗拉多大学评议会法人机构 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
AU2006274438A1 (en) 2005-07-29 2007-02-01 Australian Stem Cell Centre Limited Compositions and methods for growth of pluripotent cells
EP1922062A2 (en) 2005-09-08 2008-05-21 DSMIP Assets B.V. Method of treatment or prevention of age-related macular degeneration
EP1933870A2 (en) 2005-09-19 2008-06-25 Palingen Inc. Treatment of b cell diseases using anti-germline antibody binding agents
CN107929731A (zh) 2005-11-04 2018-04-20 健泰科生物技术公司 利用补体途径抑制剂治疗眼部疾病
WO2007112403A2 (en) 2006-03-27 2007-10-04 The Regents Of The University Of Colorado Prevention and treatment of ischemia-reperfusion injury
WO2007124299A2 (en) 2006-04-21 2007-11-01 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
ES2523640T3 (es) 2006-06-21 2014-11-28 Musc Foundation For Research Development Direccionamiento del factor H del complemento para el tratamiento de enfermedades
US7705475B2 (en) 2006-08-03 2010-04-27 Stats Chippac Ltd. Integrated circuit package system
ES2700609T3 (es) 2006-11-02 2019-02-18 Genentech Inc Anticuerpos anti-factor D humanizados y sus usos
EP2118142A2 (en) * 2007-03-14 2009-11-18 Taligen Therapeutics, Inc. Humaneered anti-factor b antibody
WO2009029669A1 (en) 2007-08-27 2009-03-05 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with factor bb specific antibodies
RU2473563C2 (ru) 2007-06-07 2013-01-27 Дженентек, Инк. АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ
CL2008003241A1 (es) 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares
SI2262831T1 (sl) 2008-03-03 2015-10-30 Novelmed Therapeutics, Inc. Protitelesa anti-properdina
MX356218B (es) 2008-08-05 2018-05-18 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5.
BRPI0921845A2 (pt) 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
US8840868B2 (en) 2009-02-04 2014-09-23 The Regents Of The University Of Colorado, A Body Corporate Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
WO2010135717A2 (en) 2009-05-21 2010-11-25 Potentia Pharmaceuticals, Inc. Complement assays and uses thereof
ME01699B (me) * 2009-07-02 2014-09-20 Musc Found For Res Dev Metode za stimulaciju regeneracije jetre
MX2012005151A (es) 2009-11-05 2012-08-23 Federico Ii University Of Naples Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
MX2012013233A (es) 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
KR20130036276A (ko) 2010-06-22 2013-04-11 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 보체 결합 3의 C3d 조각에 대한 항체들
CN103248395A (zh) 2012-02-09 2013-08-14 中兴通讯股份有限公司 一种窄带干扰抑制方法及装置
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody

Also Published As

Publication number Publication date
HK1206368A1 (en) 2016-01-08
US20080221011A1 (en) 2008-09-11
EP2826788A1 (en) 2015-01-21
EP2044111A2 (en) 2009-04-08
AU2007261315B2 (en) 2012-10-25
US8569225B2 (en) 2013-10-29
WO2007149567A2 (en) 2007-12-27
PL2044111T3 (pl) 2015-02-27
JP2009540831A (ja) 2009-11-26
US20140073572A1 (en) 2014-03-13
EP2826788B1 (en) 2017-12-13
US9212212B2 (en) 2015-12-15
AU2007261315A1 (en) 2007-12-27
US20110015127A1 (en) 2011-01-20
CA2656063A1 (en) 2007-12-27
WO2007149567A3 (en) 2008-05-02
CN101563363B (zh) 2013-01-02
JP5250548B2 (ja) 2013-07-31
DK2044111T3 (en) 2014-11-17
BRPI0712987A2 (pt) 2012-04-10
CA2656063C (en) 2016-10-18
HK1129689A1 (en) 2009-12-04
US7759304B2 (en) 2010-07-20
ES2523640T3 (es) 2014-11-28
PT2044111E (pt) 2014-11-12
CN101563363A (zh) 2009-10-21
EP2044111B1 (en) 2014-08-13

Similar Documents

Publication Publication Date Title
SI2044111T1 (sl) Ciljanje komplementa faktorja H za zdravljenje bolezni
HK1131047A1 (en) Treatment of inflammatory diseases
IL186749A0 (en) Dihydrothienopyrimidines for the treatment of inflammatory diseases
EP2004204A4 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
GB0602178D0 (en) Therapeutic treatment
IL200368A0 (en) Treatment of diseases characterized by inflammation
HK1201046A1 (en) Methods of treating ophthalmic diseases
EP2059498A4 (en) TREATMENT OF CANCER
IL193747A0 (en) New therapeutic combinations for the treatment of depression
SI2056863T1 (sl) Zdravljenje očesnih bolezni
IL208357A0 (en) Spiro-indole derivatives for the treatment of parasitic diseases
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
GB0608655D0 (en) Therapeutic Treatment
GB0610183D0 (en) Treatment of neurodegenerative diseases
EP2026822A4 (en) TOPICAL TREATMENT FOR EYE SURGERY DISEASES
ZA200905364B (en) Treatment of diseases characterized by inflammation
EP2029156A4 (en) POLY THERAPY FOR TREATING CANCER
GB0610909D0 (en) Therapeutic treatment
IL197125A0 (en) Drug combinations for treating airway diseases
IL194066A0 (en) Therapeutic composition for treatment of tinnitus
GB0623740D0 (en) Treatment of disease
GB0622136D0 (en) Treatment of gastrointestinal diseases
ZA200904660B (en) Treatment of IL-1-Beta related diseases
GB0622137D0 (en) Treatment of gastrointestinal diseases
GB0610376D0 (en) Therapeutic treatment